266 related articles for article (PubMed ID: 33314508)
1. Repeated CD45RA-depleted DLI successfully increases donor chimerism in a patient with beta-thalassemia major after haploidentical stem cell transplant.
Chan WYK; Kwok JSY; Chiang AKS; Chan GCF; Lee PPW; Ha SY; Cheuk DKL
Pediatr Transplant; 2021 Aug; 25(5):e13945. PubMed ID: 33314508
[TBL] [Abstract][Full Text] [Related]
2. Novel treatment of severe combined immunodeficiency utilizing ex-vivo T-cell depleted haploidentical hematopoietic stem cell transplantation and CD45RA+ depleted donor lymphocyte infusions.
Brodszki N; Turkiewicz D; Toporski J; Truedsson L; Dykes J
Orphanet J Rare Dis; 2016 Jan; 11():5. PubMed ID: 26768987
[TBL] [Abstract][Full Text] [Related]
3. Competitive Repopulation and Allo-Immunologic Pressure Determine Chimerism Kinetics after T Cell-Depleted Allogeneic Stem Cell Transplantation and Donor Lymphocyte Infusion.
Koster EAS; von dem Borne PA; van Balen P; van Egmond EHM; Marijt EWA; Veld SAJ; Jedema I; Snijders TJF; van Lammeren D; Veelken H; Falkenburg JHF; de Wreede LC; Halkes CJM
Transplant Cell Ther; 2023 Apr; 29(4):268.e1-268.e10. PubMed ID: 36587743
[TBL] [Abstract][Full Text] [Related]
4. Risk factors for graft-versus-host-disease after donor lymphocyte infusion following T-cell depleted allogeneic stem cell transplantation.
Koster EAS; von dem Borne PA; van Balen P; Marijt EWA; Tjon JML; Snijders TJF; van Lammeren D; Veelken H; Falkenburg JHF; Halkes CJM; de Wreede LC
Front Immunol; 2024; 15():1335341. PubMed ID: 38545096
[TBL] [Abstract][Full Text] [Related]
5. Prediction, management, and prognosis of mixed chimerism after hematopoietic stem cell transplantation in transfusion-dependent pediatric thalassemia patients.
Chen H; Li XY; Zhan LP; Fang JP; Huang K; Li Y; Weng WJ; Xu LH; Xu HG; Zhou DH
Pediatr Transplant; 2020 Dec; 24(8):e13876. PubMed ID: 33098346
[TBL] [Abstract][Full Text] [Related]
6. Immunohematologic reconstitution in pediatric patients after T cell-depleted HLA-haploidentical stem cell transplantation for thalassemia.
Isgrò A; Marziali M; Sodani P; Gaziev J; Erer B; Polchi P; Paciaroni K; Roveda A; De Angelis G; Gallucci C; Alfieri C; Simone MD; Zinno F; Isacchi G; Adorno G; Lanti A; Leti W; Aiuti F; Fraboni D; Andreani M; Lucarelli G
Biol Blood Marrow Transplant; 2010 Nov; 16(11):1557-66. PubMed ID: 20546907
[TBL] [Abstract][Full Text] [Related]
7. Low-dose donor memory T-cell infusion after TCR alpha/beta depleted unrelated and haploidentical transplantation: results of a pilot trial.
Maschan M; Blagov S; Shelikhova L; Shekhovtsova Z; Balashov D; Starichkova J; Kurnikova E; Boyakova E; Muzalevskii Y; Kazachenok A; Trakhtman P; Osipova E; Khripkova N; Zhogov V; Novichkova G; Maschan A
Bone Marrow Transplant; 2018 Mar; 53(3):264-273. PubMed ID: 29269793
[TBL] [Abstract][Full Text] [Related]
8. The value of donor lymphocyte infusions in thalassemia patients at imminent risk of graft rejection following stem cell transplantation.
Karasu GT; Yesilipek MA; Karauzum SB; Uygun V; Manguoglu E; Kupesiz A; Hazar V
Pediatr Blood Cancer; 2012 Mar; 58(3):453-8. PubMed ID: 21990066
[TBL] [Abstract][Full Text] [Related]
9. Matched Family versus Alternative Donor Hematopoietic Stem Cell Transplantation for Patients with Thalassemia Major: Experience from a Tertiary Referral Center in South India.
Swaminathan VV; Uppuluri R; Patel S; Ravichandran N; Ramanan KM; Vaidhyanathan L; Ramakrishnan B; Jayakumar I; Raj R
Biol Blood Marrow Transplant; 2020 Jul; 26(7):1326-1331. PubMed ID: 32200123
[TBL] [Abstract][Full Text] [Related]
10. Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype.
Hsieh MM; Fitzhugh CD; Weitzel RP; Link ME; Coles WA; Zhao X; Rodgers GP; Powell JD; Tisdale JF
JAMA; 2014 Jul; 312(1):48-56. PubMed ID: 25058217
[TBL] [Abstract][Full Text] [Related]
11. Donor lymphocyte infusions to displace residual host hematopoietic cells after allogeneic bone marrow transplantation for beta-thalassemia major.
Aker M; Kapelushnik J; Pugatsch T; Naparstek E; Ben-Neria S; Yehuda O; Amar A; Nagler A; Slavin S; Or R
J Pediatr Hematol Oncol; 1998; 20(2):145-8. PubMed ID: 9544166
[TBL] [Abstract][Full Text] [Related]
12. BEAM-Campath Allogeneic Stem Cell Transplant for Patients with Relapsed/Refractory Lymphoma: High Incidence of Long-Term Mixed Donor-Recipient Chimerism and the Response to Donor Lymphocyte Infusions.
Burney C; Wadhera K; Breslin P; Pearce R; Wells M; Alajangi R; Protheroe R; Marks DI; Griffin J; Robinson S
Biol Blood Marrow Transplant; 2020 Dec; 26(12):2271-2278. PubMed ID: 32890747
[TBL] [Abstract][Full Text] [Related]
13. Hematopoietic stem cell transplantation for homozygous β-thalassemia and β-thalassemia/hemoglobin E patients from haploidentical donors.
Anurathapan U; Hongeng S; Pakakasama S; Sirachainan N; Songdej D; Chuansumrit A; Charoenkwan P; Jetsrisuparb A; Sanpakit K; Rujkijyanont P; Meekaewkunchorn A; Lektrakul Y; Iamsirirak P; Surapolchai P; Satayasai W; Sirireung S; Sruamsiri R; Wahidiyat PA; Ungkanont A; Issaragrisil S; Andersson BS
Bone Marrow Transplant; 2016 Jun; 51(6):813-8. PubMed ID: 26878659
[TBL] [Abstract][Full Text] [Related]
14. Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies.
Spitzer TR; McAfee S; Sackstein R; Colby C; Toh HC; Multani P; Saidman S; Weyouth DW; Preffer F; Poliquin C; Foley A; Cox B; Andrews D; Sachs DH; Sykes M
Biol Blood Marrow Transplant; 2000; 6(3A):309-20. PubMed ID: 10905768
[TBL] [Abstract][Full Text] [Related]
15. Effect of Donor Lymphocyte Infusion From Two Types of Donors on Mixed Chimerism With Secondary Graft Failure After Allogeneic Hematopoietic Stem Cell Transplantation.
Ren RR; Ma LM; Xie YX; Tian WW; Wang T
Transplant Cell Ther; 2022 Mar; 28(3):152.e1-152.e7. PubMed ID: 34973501
[TBL] [Abstract][Full Text] [Related]
16. Haploidentical stem cell transplantation augmented by CD45RA negative lymphocytes provides rapid engraftment and excellent tolerability.
Shook DR; Triplett BM; Eldridge PW; Kang G; Srinivasan A; Leung W
Pediatr Blood Cancer; 2015 Apr; 62(4):666-73. PubMed ID: 25559618
[TBL] [Abstract][Full Text] [Related]
17. T-cell replete haploidentical donor transplantation using post-transplant CY: an emerging standard-of-care option for patients who lack an HLA-identical sibling donor.
Bashey A; Solomon SR
Bone Marrow Transplant; 2014 Aug; 49(8):999-1008. PubMed ID: 24842530
[TBL] [Abstract][Full Text] [Related]
18. Impact of prophylactic donor leukocyte infusions on mixed chimerism, graft-versus-host disease, and antitumor response in patients with advanced hematologic malignancies treated with nonmyeloablative conditioning and allogeneic bone marrow transplantation.
Dey BR; McAfee S; Colby C; Sackstein R; Saidman S; Tarbell N; Sachs DH; Sykes M; Spitzer TR
Biol Blood Marrow Transplant; 2003 May; 9(5):320-9. PubMed ID: 12766882
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of donor lymphocyte infusion for treatment of mixed donor chimerism after a reduced-intensity preparative regimen for pediatric patients with nonmalignant diseases.
Haines HL; Bleesing JJ; Davies SM; Hornung L; Jordan MB; Marsh RA; Filipovich AH
Biol Blood Marrow Transplant; 2015 Feb; 21(2):288-92. PubMed ID: 25464116
[TBL] [Abstract][Full Text] [Related]
20. Donor Lymphocyte Infusion-Mediated Graft-versus-Host Responses in a Preclinical Swine Model of Haploidentical Hematopoietic Cell Transplantation.
Duran-Struuck R; Matar AJ; Crepeau RL; Teague AGS; Horner BM; Pathiraja V; Spitzer TR; Fishman JA; Bronson RT; Sachs DH; Huang CA
Biol Blood Marrow Transplant; 2016 Nov; 22(11):1953-1960. PubMed ID: 27543159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
